New CFO at WuXi PharmaTech
This article was originally published in Scrip
Executive Summary
The China-based contract research organisation WuXi PharmaTech has named Edward Hu chief financial officer. He has served as chief operating officer since January 2008 and was previously acting CFO from February 2009 to May 2010. Hao Zhou, the company's current CFO, is leaving the company. Charles River Laboratories recently conceded to shareholder pressure and terminated its acquisition of WuXi, paying the CRO a $30 million break-up fee (scripintelligence.com, 30 July 2010).
You may also be interested in...
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.